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Accepted 27 February 2008AbstractMisoprostol, a synthetic prostaglandin E1 analog, is initially used to prevent peptic ulcer. The initial US Food and Drug Administration-
approved indication in the product labeling is the treatment and prevention of intestinal ulcer disease resulting from nonsteroidal anti-
inflammatory drugs use. In recent two decades, misoprostol has approved to be an effective agent for termination of pregnancy in various
gestation, cervical ripening, labor induction in term pregnancy, and possible management of postpartum hemorrhage. For the termination of
second-trimester pregnancy using the combination of mifepristone and misoprostol seems to have the highest efficacy and the shortest time
interval of abortion. When mifepristone is not available, misoprostol alone is a good alternative. Misoprostol, 400 mg given vaginally every
3e6 hours, is probably the optimal regimen for second-trimester abortion. More than 800 mg of misoprostol is likely to have more side effects,
especially diarrhea. Although misoprostol can be used in women with scarred uterus for termination of second-trimester pregnancy, it is rec-
ommended that women with a scarred uterus should receive lower doses and do not double the dose if there is no initial response. It is also
important for us to recognize the associated teratogenic effects of misoprostol and thorough consultation before prescribing this medication to
patients regarding these risks, especially when failure of abortion occurs, is needed.
Copyright  2011, Taiwan Association of Obstetrics & Gynecology. Published by Elsevier Taiwan LLC. All rights reserved.
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Misoprostol, a synthetic prostaglandin E1 (PGE1) analog, is
initially used to prevent peptic ulcer. The initial Food and Drug
Administration (FDA)-approved indication in the product label
is the treatment and prevention of intestinal ulcer disease
resulting from nonsteroidal anti-inflammatory drugs (NSAIDs)
use. However, because of its cervical ripening and uterotonic
properties, misoprostol has begun to be abused for illegal* Corresponding author. Department of Obstetrics and Gynecology, Mackay
Memorial Hospital, 92, Section 2, Chung-San North Road, Taipei, Taiwan.
E-mail address: cpc_mmh@yahoo.com (C.-P. Chen).
1028-4559/$ - see front matter Copyright  2011, Taiwan Association of Obstetri
doi:10.1016/j.tjog.2011.07.003abortion since late 1980s. After serial trials in recent two
decades, misoprostol became one of the most useful drugs in
termination of pregnancy and also for induction of labor.
In this review article, we will talk about the development
of misoprostol and the use of misoprostol in termination of
second-trimester pregnancy.The pharmacologic properties of misoprostol
Misoprostol is a synthetic 15-deoxy-16-hydroxy-16-methyl
analog of PGE1 and is water soluble. The most common
commercial preparation available in Taiwan is Cytotec (Pfizer,
New York, NY, USA) tablets (200 mg) that contains thecs & Gynecology. Published by Elsevier Taiwan LLC. All rights reserved.
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methylcellulose, microcrystalline cellulose, and sodium starch
glycolate [1]. The bioactivity of misoprostol is characterized
by rapid absorption, extensive metabolism, and rapid excre-
tion. After oral administration, the Tmax of misoprostol acid is
12 3 minutes with a terminal half-life of 20e40 minutes [2].
There is high variability of plasma levels of misoprostol acid
after single doses showing a linear relationship with dose over
the range of 200e400 mg. No accumulation of misoprostol acid
was noted in multiple dose studies and a plasma steady state
was achieved within 2 days. Misoprostol is mainly metabolized
in the liver, and less than 1% excreted in the urine [3]. There is
no known drug interaction of misoprostol.
In the beginning, misoprostol was only used as an oral tablet,
but many studies showed many different routes of administra-
tion, such as vaginal route, sublingual route, and buccal route [4].
Some pharmacokinetic studies show the systemic bioavailability
with vaginal route is three times higher than that of oral route.
Another study from Lumbiganon et al [5] concluded that
sublingual misoprostol reached peak concentration in the
shortest time and had the highest bioavailability comparison
with vaginal and oral routes.
The development of misoprostol
In 1982, misoprostol was confirmed to have antisecretory
activity and mucosal protective effect on the gastrointestinal
mucosa of human beings [6]. It became the first medication
used in a multicenter, randomized, double-blind trial for
patients with peptic ulcer disease since 1985 [7]. Since then,
misoprostol was widely marketed for the prevention and
treatment of peptic ulcer disease [8]. The oral tablet of miso-
prostol was approved by the FDA in 1988 for the prevention
and treatment of gastric ulcers associated with the use of
NSAIDs.
However, misoprostol became a widely used abortifacient
after its introduction since 1986, especially by women in
countries where abortion was illegal or limited in special
conditions [2]. In 1987, the first report of the potential effect of
misoprostol for the termination of pregnancy was published
[9], partial or complete abortion, vaginal bleeding, and soft-
ening of the cervix were all significantly increased after the
use of misoprostol. Another report about the abuse of miso-
prostol for illegal abortion was published in 1991 [10]. In fact,
most of these publications came from Brazil and other coun-
tries in South and Central America. Lower cost, convenience
of use, and less traumatic than other abortion methods were
the reasons of abuse. Thereafter, several trials about miso-
prostol for termination of pregnancy were reported and
showed a strong evidence for the efficacy and relative safety in
obstetrical and gynecological practice.
In fact, misoprostol had drawn out a debate in the literature
from the antiabortion lobby, the manufacturer (Searle),
American College of Obstetricians and Gynecologists, and
a lots of conflict and fight occurred between them. After some
issues, on April 17, 2002, the FDA finally approved a new label
for the use of misoprostol during pregnancy [11]. The new labelof use for misoprostol suggests that the contraindication is only
for pregnant women who are using the medication to reduce the
risk of NSAID-induced gastric ulcers. Since then, misoprostol
becomes a legitimate part of the FDA-approved regimen for
use with mifepristone to induce abortion in early pregnancy
and is also recognized for its use for induction of labor [2]. And
the World Health Organization also recommended the use of
misoprostol in termination of pregnancy in various gestations
[12]. In recent two decades, misoprostol has approved not only
to be an effective agent for termination of pregnancy in various
gestation and also useful in cervical ripening, labor induction in
term pregnancy, treatment of incomplete abortion [13], and
possible management of postpartum hemorrhage [14].Termination of pregnancy with misoprostol
Of the various PG analogs, misoprostol is the drug of
choice as it is cheap, stable at room temperature, and available
in most countries. It has been used orally, vaginally, or sub-
lingually for medical abortion.
In the 1970s, several PGs have been shown to have abor-
tifacient, which is effective for inducing abortion [15]. By the
1980s, more analogs of PG were reported to be effective for
abortion, such as parenteral sulprostone and intravaginal
gemeprost. However, the adverse side effects of these medi-
cations and the higher cost made them unsuitable as single
agents for abortion. In 1987, the first report of the potential
effect of misoprostol for the termination of the first-trimester
pregnancy was published [16]. In 1991, Norman et al [17]
reported the effect of misoprostol on uterine contractility
and showed that misoprostol, with or without mifepristone,
resulted in augmentation of the amplitude and frequency of
uterine contractions. This publication was a landmark study of
misoprostol and let it be a promising uterotonic agent. After
this report, many researchers became interested in the effect of
misoprostol as a cervical priming agent before surgical abor-
tion or medical abortion.Termination of second-trimester pregnancy
The ability of early prenatal diagnosis of fetal anomalies
has expanded the indications for termination of pregnancy in
the second trimester [18]. A variety of methods such as dila-
tion and evacuation (D&E), systemic medications, intra-
amniotic or extra-amniotic abortifacients, and hysterotomy
have been used [19]. The traditional use of D&E in the second
trimester basically is safe and effective. However, its safety
depends on the surgeon’s skill and experience, and it may
cause psychologically trauma. Thus, less traumatic and
noninvasive methods for termination of pregnancy seem to be
the better choices. Furthermore, if the fetus can be delivered
intact, it can give us more detailed information for further
pathological and cytogenetic diagnosis. This information is
very important for prenatal counseling in the future. There-
fore, an alternative method is required to replace the use of
D&E.
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277C.-J. Lin et al. / Taiwanese Journal of Obstetrics & Gynecology 50 (2011) 275e282Many alternative methods for medical termination of
second-trimester pregnancy are recommended, including intra-
amniotic hypertonic saline or urea, intra-amniotic PGF2a
infusion, oxytocin infusion, and vaginal gemeprost adminis-
tration [20].
Leihair et al [21] first described the use of transvaginal
misoprostol for expulsion of arrested gestational product in the
second trimester in 1989. Since then, many studies have been
reported. Baird et al [22] reported that misoprostol has effects
on uterine tone similar to that of other PGs. Bugalho et al [23]
and Yapar et al [24] published the further assessment of
intravaginal administration of misoprostol. Fetal expulsion
was successfully achieved in almost 90% of 132 cases who
received 800e1600 mg misoprostol (800 mg dosage with
successively reduced to 600 mg, 400 mg, and 200 mg). The
mean abortion time was 14.3 hours. Elsheikh et al [25]
concluded that the high efficacy and low incidence of side
effects make misoprostol an useful alternative for second-
trimester termination of pregnancy.M
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0There were some reports talk about the use of combination
of mifepristone and misoprostol, which could possibly fasten
the mean abortion time and improve the efficacy. Ashok and
Templeton [26] reviewed 500 consecutive cases of medical
abortion in second trimester of pregnancy and concluded that
the combination of mifepristone followed by misoprostol
provided a noninvasive and effective regimen for this indica-
tion. Another present study reported that combination of
mifepristone followed by misoprostol could achieve a high
successful rate (95.9%) of abortion within 24 hours and mean
abortion time was 6 hours [27].
In Table 1 [26e33], we can see the results from those
studies with the regimen of mifepristone and misoprostol. The
mean abortion time after the use of misoprostol ranged from
5.4 hours to 10 hours. The conventional timing of misoprostol
administration after mifepristone for second-trimester medical
abortion is 36e48 hours. Li et al [34,35] had reported their
simultaneous use of mifepristone and misoprostol for early
pregnancy termination with a better result. However, Chai et al
[36] published their report and supported that simultaneous
use of mifepristone and misoprostol for second-trimester
medical abortion is not as effective as the regimen using
a 36e38-hour dosing interval.
Thus, the pretreatment with mifepristone (200 mg)
36e48 hours before administration of misoprostol is a good
choice to terminate the mid-trimester pregnancy.fe
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]When mifepristone is not available, misoprostol alone is
also an efficient method. There were many different studies
talking about this issue, including the variation in dosage,
time interval, and the route of administration were well
discussed.
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Some studies compare the efficacy with other modalities,
such as intra-amniotic PGF2a infusion, oxytocin infusion,
and vaginal gemeprost administration. Three randomized
controlled trials compared vaginal misoprostol with gemeprost
amongwomenwith live and dead fetuses in the second trimester.
All of them found that misoprostol is as effective as, or more
effective than, gemeprost. Jain et al [37] showed that intravaginal
misoprostol administration is at least as effective as PGE2 gel for
second-trimester pregnancy termination. In our report in 2000
[19], the comparison of intravaginal misoprostol administration
(800 mg) with extra-amniotic foley traction using PGF2a infu-
sion for termination of second-trimester pregnancy resulted in
similar successful rates of 92.8% and 88.5%, respectively, and
a shorter mean abortion time (10.4 6.7 hours) for the miso-
prostol group. Another study by Ghorab and El Helw [38]
compared endocervical misoprostol and extra-amniotic PGF2a
and showed that misoprostol was more effective. Thus, it seems
that the regimen ofmisoprostol alone is as effective or evenmore
effective than other regimens.
About the dosage
The required amount of misoprostol not only decreases
with increasing gestational age, but has also been found to be
lower in women with a died fetus [4]. In 2002, Dickinson and
Evans [39] introduced a randomized trial comparing three
regimens of intravaginal misoprostol (200 mg hourly; 400 mg 6
hourly; 600 mg loading dose followed by 200 mg 6 hourly)
suggested that the 400 mg regimen was preferred. Their latterTable 2
Misoprostol alone
Author No. of
individuals
Gestational
age (wk)
Misoprostol route M
d
Dickinson et al [43] 100 14e28 Vaginally (Group 2) 2
Wong et al [44] 140 14e20 Vaginally (Group b) 4
Jain et al [37] 100 12e22 Vaginally
Vaginally
2
2
Wong et al [42] 148 14e20 Vaginally
Vaginally
4
4
Bebbington et al [45] 114 Mid-trimester Orally 2
Dickinson and Evans [39] 150 14e30 Vaginally
Vaginally
Vaginally
2
4
6
Tang et al [46] 224 12e20 Sublingually
Vaginally
4
4
Bhattacharjee et al [47] 300 13e20 Sublingually
Vaginally
4
4
Carbonell et al [48] 210 12e20 Vaginally
Vaginally
6
4
Caliskan et al [49] 162 15e22 Sublingually
Sublingually
1
2
von Hertzen et al [50] 681 13e20 Sublingually
Vaginally
4
4
Chaudhuri et al [51] 185 12e20 Vaginally
Vaginally
4
4
Cheng et al [52] 16 12e25 Vaginally 2publication of randomized controlled trial on a comparison of
oral and vaginal misoprostol (400 mg orally 3 hourly; 400 mg
vaginally 6 hourly; vaginally 600 mg loading dose then 200 mg
orally 3 hourly) showed similar results. The oral regimens
showed significant inferiority over the vaginal regimen in the
abortion rate within 24 hours. The increased dosage was
associated with a higher incidence of side effects [40]. Some
authors recommended that more than 800 mg of misoprostol is
likely to have more side effects, especially diarrhea [41,42].
The studies in Table 2 [42e52] showed that doses of 400 mg
seem like an effective dosage with good efficacy.
About the interval of use
In the studies by Wong et al [44], they suggested that
misoprostol could be administered at longer than 3-hour
intervals to reduce its side effects, and the 3-hour regimen
provides a significantly shorter abortion interval and higher
percentage of successful abortion within 48 hours than the 6-
hour interval group. The incidence of side effects was
similar in the two groups excluding fever. Another pilot study
from Taiwan showed that oral administration of 200 mg
misoprostol at hourly intervals is also a promising method for
termination of mid-trimester pregnancies, the means of
induction to delivery interval was 12.0 hours with 81.3%
women undergoing vaginal delivery within 24 hours, and the
side effects was not significantly increased [52], but the case
number is too small to have a new conclusion. The latest
Cochrane Database reviewed four randomized controlled trials
for termination of mid-trimester pregnancy (12e28 weeks’isoprostol
ose (mg)
Misoprostol
time interval
Abortion rate
within 24 h
Induction-abortion
interval mean (h)
00 q6 h 4 74.9% 16.9
00 q3 h 5 73% 14.1
00
00
q6 h 48 h
q12 h 48 h
80.9%
86.5%
13.8
14.0
00
00
q3 h 5
q6 h 3
80%
60.8%
15.2
19
00 q1 h 3 followed
by 400 mg q4 h 6
38.5% 34.5
00
00
00
q6 h 48 h
q6 h 48 h
Followed by
200 mg q6 h 48 h
58.8%
76%
79.6%
18.2
15.1
13.2
00
00
q3 h 5
q3 h 5
72%
86%
12.2
10.5
00
00
q3 h 8
q3 h 8
79.8%
85.9%
12
12.3
00
00
q6 h 4
q4 h 5
98.1%
94.3%
10.7
11.5
00
00
q2 h
q2 h
92.6%
91.4%
7.4
7.6
00
00
q3 h 8
q3 h 8
79.8%
85.9%
12
12.3
00
00
q6 h 4
q12 h 4
56.5% (<12 h)
25.8% (<12 h)
12.59
16.41
00 q1 h 12 h
followed by 400 mg q1 h
81.3% 12
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intervals [53]. From Table 2, we can see that most of these
studies use misoprostol with the time interval from 3 hours to
6 hours, and their result had a good abortion rate and short
induction to abortion interval. It seems that 3e6 hours interval
is a good choice for mid-trimester termination.
About the route of administration
Many studies investigated the different routes of adminis-
tration of misoprostol, such as orally, vaginally, buccally, and
sublingually [54], even with titrated oral misoprostol has been
reported [55]. In 2000, Ngai et al [29] suggested that oral
misoprostol is as effective as vaginal misoprostol if the dose was
doubled. In the following year, a randomized trial of oral versus
vaginal misoprostol was conducted by Gilbert and Reid [56] and
suggested that the vaginal route of administration was signifi-
cantly more effective. Cabrera et al [57] conducted a meta-
analysis of published randomized controlled trials that
compared sublingual and vaginal routes, and they said that
sublingual and vaginalmisoprostol are equally safe and effective
for mid-trimester pregnancy termination. The 2011 Cochrane
Database Systemic Review also recommended that the optimal
route for administrating misoprostol is vaginally [53].
There are some factors that influence the induction-abortion
interval. Dickinson and Doherty [58] published that nulliparity,
younger maternal age, and increasing gestational age were
associated with a longer induction-abortion interval, and the
types of fetal anomaly had no impact on abortion duration.
Dilek et al [59] studied the possible effect of cervical length on
second-trimester pregnancy termination. They used a cutoff of
36 mm of cervical length by transvaginal measurement before
administration of misoprostol and found that the length of
cervix was not correlated with successful termination of preg-
nancy within 24 hours. Chou et al [60] told about the moni-
toring medical abortion with ultrasonogram and serum human
chorionic gonadotropin.
From all the above studies and the list in Table 2, miso-
prostol, 400 mg given vaginally every 3e6 hours, is probably
the optimal regimen for second-trimester abortion [4,61].The scarred uterusThere were some case reports about uterine rupture in
scarred uterus after the administration of misoprostol. Dick-
inson [62] published his results about scarred uterus. Miso-
prostol was used to induce abortion with 400 mg vaginally
every 6 hours and the presence of a prior uterine scar did not
impact on abortion duration. Thus he concluded that, in
second-trimester abortion, the use of misoprostol in women
with prior cesarean delivery was not associated with an excess
of complications compared with women with unscarred uteri.
Berghella et al [63] published their data about women with
one prior low-transverse caesarean birth who underwent
termination of pregnancy with misoprostol, the incidences of
uterine rupture is 0.4%, the incidence of hysterectomy is 0%,
and the incidence of transfusion is 0.2%. Fawzy and Abdel-
Hady [64] used misoprostol 200 mg vaginally with 6 hoursintervals on the 1st day and double the dose to 400 mg with the
same intervals since the 2nd day in the women with three or
more prior cesarean sections. This study had a 90.3%
successful rate without any adverse outcome. However, for
safety, it is recommended that women with a scarred uterus
should receive lower doses of misoprostol and do not double
the dose if there is no initial response [4].The outcome of subsequent pregnanciesIn 2009, Mirmilstein et al [65] reviewed the women who
had undergone a misoprostol mid-trimester termination in
their last pregnancy with those of a similar cohort of women
without a history of use of misoprostol. It showed a possibility
that termination of mid-trimester pregnancy with misoprostol
increases the risk of preterm or very preterm delivery in
a subsequent pregnancy. However, another case-control study
was reported by Winer et al [66] in the same year, it included
245 cases and 490 controls and the result provided reassurance
that induced abortion with misoprostol during the first or
second trimester of pregnancy is safe for subsequent preg-
nancies. Larger studies are needed to confirm both of these
results.Adverse effects of misoprostolMany adverse effects of misoprostol have been reported,
include diarrhea, abdominal pain, headache, menstrual cramps,
nausea and flatulence, chills, shivering, and fever, all of them
are dose-dependent. The most common side effects are chills/
shivering (38%), fever (35%), and diarrhea (24%). In pregnant
women, chills, shivering, and fever are more commonly
reported side effects [1]. Fever up to 40C are associated with
higher dose of misoprostol (e.g. 800 mg), shorter intervals, and
oral or sublingual routes [5]. However, fever is transient and
easily disappears after cooling and antipyretics. Diarrhea is
another common adverse reaction, about 35% women were
affected after the use of misoprostol [67]. Fortunately, it is mild
and self-limited even without any management. As we know
that the increased dosagewas associated with a higher incidence
of side effects, more than 800 mg of misoprostol was likely to
have side effects, especially diarrhea [68]. Besides, fever was
more common in the use of misoprostol by means of vaginal
route.
Furthermore, misoprostol acid was found to be secreted in
the colostrum within 1 hour after oral administration of 600 mg
of misoprostol, thus we should avoid using misoprostol in
nursing mothers because it may cause diarrhea in the baby [69].Teratogenic effects of misoprostolThe package warned that misoprostol could cause birth
defects if given to pregnant women. Teratogenic effects were
reported with failed abortion and attempted to continue
pregnancy after administration of misoprostol. Because this
drug is listed as a pregnancy category X, the effects of fetus
exposure to misoprostol in utero became highly concerned.
280 C.-J. Lin et al. / Taiwanese Journal of Obstetrics & Gynecology 50 (2011) 275e282In 1993, the first report of seven infants whose mothers try
to abort using misoprostol in the first trimester of pregnancy
without success were born with limb defects and four of them
had Mo¨bius syndrome [70]. In the following literatures, the
association of exposure of misoprostol during the first
trimester of pregnancy and the occurrence of congenital
abnormalities, such as skull defects, cranial nerve palsies,
facial malformations, and limb defects had been reported. In
1998, Gonzalez et al [71] showed the distinctive phenotypes
included equinovarus with cranial nerve defects, arthrogry-
posis of legs, and terminal transverse limb defects. They
suggested that these congenital abnormalities were due to
vascular disruption causing by the uterine contractions
induced by misoprostol. Holmes [72] also concluded that the
effect of vascular disruption caused by misoprostol may
induce fetal limb defects. Another system review in 2006
showed that increased risks of congenital anomalies related to
the use of misoprostol were found more significantly in
Mo¨bius sequence (congenital facial paralysis with or without
limb defects) and terminal transverse limb defects than any
other congenital defect [73]. However, the risk of fetal
abnormality after the use of misoprostol is low, the estimated
risk was less than 1% among those exposed fetus [74].
It is important for us to recognize these associated terato-
genic effects and thorough consultation before prescribing this
medication to patients regarding these risks, especially when
failure of abortion occurs, is needed [75].
Conclusions
Multiple trials have proved that misoprostol is an effective
agent for termination of second-trimester pregnancy. For
termination of second-trimester pregnancy, using the combina-
tion of mifepristone and misoprostol seems to have the highest
efficacy and shortest abortion time interval. When mifepristone
is not available, misoprostol alone is a good alternative. Miso-
prostol, 400 mg given vaginally every 3e6 hours, is probably the
optimal regimen for second-trimester abortion. More than
800 mg of misoprostol is likely to have more side effects,
especially diarrhea.
Although, misoprostol can be used in women with scarred
uterus for termination of second-trimester pregnancy, it is
recommended that women with a scarred uterus should receive
lower doses and do not double the dose if there is no initial
response.
It is important for us to recognize the associated teratogenic
effects of misoprostol and thorough consultation before
prescribing this medication to patients is needed.
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